Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Gastoldi

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|July 19, 2021
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration PlasmapheresisDiego Curtò, Federica Tomatis, Sara Gastoldi, et al.
Thrombosis and Haemostasis|February 5, 2009
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodiesElena Bresin, Sara Gastoldi, Erica Daina, et al.
Thrombosis and Haemostasis|March 1, 2005
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathiesMaria Piedad Ruiz-Torres, Federica Casiraghi, Miriam Galbusera, et al.
Frontiers in Medicine|November 23, 2020
Molecular Studies and an <i>ex vivo</i> Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 VariantRossella Piras, Paraskevas Iatropoulos, Elena Bresin, et al.
Frontiers in Immunology|February 27, 2023
An <i>ex vivo</i> test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndromeSara Gastoldi, Sistiana Aiello, Miriam Galbusera, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 28, 2017
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular ThrombosisSerena Bettoni, Miriam Galbusera, Sara Gastoldi, et al.
Blood|April 14, 2005
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case reportMiriam Galbusera, Elena Bresin, Marina Noris, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 7, 2011
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosisMarina Morigi, Miriam Galbusera, Sara Gastoldi, et al.
Frontiers in Immunology|May 27, 2024
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activityTodor Tschongov, Swagata Konwar, Andreas Busch, et al.
Journal of the American Society of Nephrology : JASN|October 11, 2017
Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic SyndromeElena Goicoechea de Jorge, Agustín Tortajada, Sheila Pinto García, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|July 19, 2021
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration PlasmapheresisDiego Curtò, Federica Tomatis, Sara Gastoldi, et al.
Thrombosis and Haemostasis|February 5, 2009
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodiesElena Bresin, Sara Gastoldi, Erica Daina, et al.
Thrombosis and Haemostasis|March 1, 2005
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathiesMaria Piedad Ruiz-Torres, Federica Casiraghi, Miriam Galbusera, et al.
Frontiers in Medicine|November 23, 2020
Molecular Studies and an <i>ex vivo</i> Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 VariantRossella Piras, Paraskevas Iatropoulos, Elena Bresin, et al.
Frontiers in Immunology|February 27, 2023
An <i>ex vivo</i> test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndromeSara Gastoldi, Sistiana Aiello, Miriam Galbusera, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 28, 2017
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular ThrombosisSerena Bettoni, Miriam Galbusera, Sara Gastoldi, et al.
Blood|April 14, 2005
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case reportMiriam Galbusera, Elena Bresin, Marina Noris, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 7, 2011
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosisMarina Morigi, Miriam Galbusera, Sara Gastoldi, et al.
Frontiers in Immunology|May 27, 2024
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activityTodor Tschongov, Swagata Konwar, Andreas Busch, et al.
Journal of the American Society of Nephrology : JASN|October 11, 2017
Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic SyndromeElena Goicoechea de Jorge, Agustín Tortajada, Sheila Pinto García, et al.
Pageof 4